Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHENASDAQ:BDRXNASDAQ:CNTBNASDAQ:FREQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$4.34+0.2%$4.04$1.00▼$5.87$38.40M0.8143,432 shs11,130 shsBDRXBiodexa Pharmaceuticals$1.03+29.3%$1.30$0.78▼$41.50$29.10M1.211.08 million shs54.85 million shsCNTBConnect Biopharma$1.00-7.4%$0.79$0.51▼$1.73$60.01M-0.2758,876 shs157,544 shsFREQFrequency Therapeutics$0.30$0.58$0.18▼$16.00$10.94M0.84822,537 shs309,164 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics-1.81%-6.48%+8.52%+9.07%+136.61%BDRXBiodexa Pharmaceuticals-23.43%-30.15%-37.79%-65.97%+79,629,900.00%CNTBConnect Biopharma+10.22%+35.85%+43.81%+35.00%-34.55%FREQFrequency Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATHEAlterity Therapeutics1.8997 of 5 stars3.33.00.00.00.01.70.0BDRXBiodexa Pharmaceuticals0.2846 of 5 stars0.03.00.00.02.20.00.0CNTBConnect Biopharma3.3619 of 5 stars3.55.00.00.02.02.50.6FREQFrequency TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHEAlterity Therapeutics 2.50Moderate Buy$12.00176.50% UpsideBDRXBiodexa Pharmaceuticals 0.00N/AN/AN/ACNTBConnect Biopharma 3.00Buy$7.00599.93% UpsideFREQFrequency Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest FREQ, CNTB, ATHE, and BDRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$7.003/31/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHEAlterity TherapeuticsN/AN/AN/AN/A$1.04 per shareN/ABDRXBiodexa Pharmaceuticals$470K80.08N/AN/A$0.29 per share3.55CNTBConnect Biopharma$26.03M2.13N/AN/A$1.67 per share0.60FREQFrequency Therapeutics$14.07M0.78N/AN/A$1.96 per share0.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHEAlterity Therapeutics-$12.54MN/A0.00∞N/AN/AN/AN/A8/4/2025 (Estimated)BDRXBiodexa Pharmaceuticals-$7.32MN/A0.00N/AN/AN/AN/AN/A7/11/2025 (Estimated)CNTBConnect Biopharma-$15.63MN/A0.00N/AN/AN/AN/AN/A9/5/2025 (Estimated)FREQFrequency Therapeutics-$81.58M-$1.89N/AN/AN/AN/A-107.67%-61.40%N/ALatest FREQ, CNTB, ATHE, and BDRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CNTBConnect Biopharma-$0.26-$0.19+$0.07-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHEAlterity TherapeuticsN/AN/AN/AN/AN/ABDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/AFREQFrequency TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHEAlterity TherapeuticsN/A3.84N/ABDRXBiodexa Pharmaceuticals0.011.751.75CNTBConnect Biopharma0.0110.2510.25FREQFrequency TherapeuticsN/A5.815.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHEAlterity Therapeutics2.14%BDRXBiodexa Pharmaceuticals17.51%CNTBConnect Biopharma58.72%FREQFrequency Therapeutics13.18%Insider OwnershipCompanyInsider OwnershipATHEAlterity Therapeutics38.80%BDRXBiodexa Pharmaceuticals0.34%CNTBConnect Biopharma22.60%FREQFrequency Therapeutics16.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableBDRXBiodexa Pharmaceuticals2036.54 million36.42 millionNot OptionableCNTBConnect Biopharma11055.56 million43.00 millionOptionableFREQFrequency Therapeutics4636.52 million30.39 millionNot OptionableFREQ, CNTB, ATHE, and BDRX HeadlinesRecent News About These CompaniesMolecular Response to Therapy Linked With Event-Free Survival in PVMay 23, 2025 | ajmc.comIn uncertain times, focus on the mission, Cognito Therapeutics leaders sayApril 16, 2025 | medicaldesignandoutsourcing.comTrevi Therapeutics RIVER trial meets primary endpointMarch 10, 2025 | markets.businessinsider.comTrevi Therapeutics RIVER trial meets primary endpointMarch 10, 2025 | markets.businessinsider.comProgentos Therapeutics CEO Chris Loose named board member and chair of the Fellowship and Programs Council for Hertz FoundationFebruary 27, 2025 | eurekalert.orgKRRO stock touches 52-week low at $29.8 amid yearly slumpFebruary 11, 2025 | msn.compay n play casino trustlyDecember 29, 2024 | bwdisrupt.businessworld.inSilence Therapeutics Advances Promising siRNA Therapy for PVDecember 10, 2024 | markets.businessinsider.comFrequency Exchange and gethealthy.store Launch "Nikki" Wellness Technology Into 1,000+ Clinic StoresDecember 5, 2024 | finance.yahoo.comFrequency Exchange Welcomes Former NHL Star and Current President of the Boston Bruins Cam Neely to Its Advisory BoardNovember 22, 2024 | finance.yahoo.comCognito Therapeutics highlights cost-effectiveness of neuromod for Alzheimer’sNovember 20, 2024 | massdevice.comLeamington hospital launches revolutionary robotic prostate treatment therapy for menNovember 14, 2024 | msn.comPromising Developments at Astria Therapeutics Bolster Buy RecommendationNovember 14, 2024 | markets.businessinsider.comStudy finds Tetris-based therapy can ease post-traumatic stress disorder symptomsNovember 14, 2024 | msn.com‘Most depressing, low-energy, low-frequency city:’ Kolkata India’s ‘dirtiest city’ says X user, triggering heated debate onlineNovember 7, 2024 | timesofindia.indiatimes.comRapport Therapeutics Reports Third Quarter Financials and Provides Business UpdateNovember 7, 2024 | markets.businessinsider.comModulating CD39 expression to enhance CAR-T cell therapy against hepatocellular carcinomaNovember 5, 2024 | news-medical.netTherapy using a digital avatar could help patients suffering from psychosis, study saysNovember 4, 2024 | msn.comNew research upends long-held beliefs about romantic love and sexual frequencyNovember 4, 2024 | msn.comTG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue GuidanceNovember 4, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFREQ, CNTB, ATHE, and BDRX Company DescriptionsAlterity Therapeutics NASDAQ:ATHE$4.34 +0.01 (+0.23%) Closing price 03:58 PM EasternExtended Trading$4.32 -0.02 (-0.58%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Biodexa Pharmaceuticals NASDAQ:BDRX$1.03 +0.23 (+29.35%) Closing price 04:00 PM EasternExtended Trading$1.01 -0.02 (-1.94%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Connect Biopharma NASDAQ:CNTB$1.00 -0.08 (-7.40%) Closing price 03:58 PM EasternExtended Trading$1.01 +0.01 (+0.99%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Frequency Therapeutics NASDAQ:FREQFrequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
